Multimodal treatment for malignant pleural mesothelioma
Mené sur 151 patients atteints d'un mésothéliome pleural malin (durée médiane de suivi : 54,2 mois), cet essai international de phase II évalue l'efficacité, du point de vue de la survie sans récidive locorégionale, et la toxicité d'une radiothérapie hémithoracique à forte dose de rayonnements ionisants après une chimiothérapie néoadjuvante par cisplatine-pémétrexed en combinaison ou non avec une pneumonectomie extrapleurale
European countries where asbestos was used extensively between the 1940s and the 1980s are experiencing an epidemic of malignant pleural mesothelioma. Mesothelioma is likely to continue to afflict people in countries where asbestos use remains unregulated and where 125 million people are believed to be exposed in the workplace.1 Attempts to cure mesothelioma by pleuropneumonectomy were halted in the 1970s because of failure to control the disease. In the 1990s extirpative surgery was reconsidered, renamed extrapleural pneumonectomy and combined with chemotherapy, radiotherapy, or both, in various treatment protocols.
The Lancet Oncology , commentaire, 2014